The October 2026 HHS compounding change: what it means and what it doesn't

By The Peptide Informative editorial team · 3 Nov 2026 · 7 min read

Six peptides can now be compounded by licensed pharmacies under strict conditions. That is not FDA approval, and it does not cover research-use-only sellers.

On 28 October 2026, the U.S. Department of Health and Human Services announced a limited, interim enforcement-discretion policy for the compounding of six peptides. The headlines moved fast. Here is what the policy does and what it doesn't, based on analyses by Foley & Lardner and McDermott Will & Schulte.

Which peptides, and by which routes

• BPC-157: subcutaneous, intramuscular, oral and topical
• Epitalon: subcutaneous or intramuscular, intermittent courses
• KPV: topical and oral
• MOTS-c: subcutaneous or intramuscular
• Semax: intranasal
• TB-500: subcutaneous or intramuscular

Where it came from

In July 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) narrowly voted to recommend six of the seven peptides it considered for the 503A bulks list, despite opposition from FDA career scientists (Foley). The seventh, emideltide (DSIP), was not recommended, and the policy does not cover it (McDermott).

What it means

• Licensed 503A compounding pharmacies can make these six peptides, for the listed routes, without FDA enforcement action, as long as they meet the policy's conditions.
• The conditions, as summarized by the law firms, include: a bulk substance from an FDA-registered facility with a valid certificate of analysis, CGMP manufacture, a single active ingredient, documented bioavailability for oral forms, only 510(k)-cleared syringes, a label stating “This is a compounded drug product. Not for resale.”, and adverse-event reporting to MedWatch.

What it doesn't mean

• It is not FDA approval. None of the six is an approved drug, and the policy makes no finding that they are safe or effective.
• It does not add them to the 503A bulks list. It is interim discretion ahead of formal rulemaking.
• It does not cover research-use-only sellers. FDA's August 2026 warning letters to five online vendors made clear that a “research use only” label doesn't protect a seller whose website, dosing guidance, calculators or bundled bacteriostatic water show the products are meant for people (ArentFox Schiff).
• It does not change the evidence. Our BPC-157 profile still rates the human evidence as very low certainty.

What to watch

• Written comments on the policy are due 13 November 2026 (Foley).
• The next PCAC meeting, expected before February 2027, is set to consider LL-37, GHK-Cu, dihexa, Melanotan II and PEG-MGF (ArentFox Schiff).
• Other peptides remain on FDA's Category 2 list of substances that may present significant safety risks, including ibutamoren mesylate (503A and 503B) and, for 503B outsourcing facilities, GHRP-2, GHRP-6 and ipamorelin acetate (FDA).